[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337145-105":59,"doc-detail-337145-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","zuojin-pill-alleviates-precancerous-lesions-of-gastric-cancer-mekerkc-myc-pathway-network-pharmacology-molecular-dynamics-and-experimental-validation","Zuojin Pill Alleviates Precancerous Lesions of Gastric Cancer - MEK/ERK/c-Myc Pathway Network Pharmacology Molecular Dynamics and Experimental Validation","","Zuojin Pill (ZJP), a traditional Chinese medicine, is evaluated for its ability to alleviate precancerous lesions of gastric cancer (PLGC), a high-risk stage in gastric cancer progression. The study combines ultra-high performance liquid chromatography–mass spectrometry to identify active components with network pharmacology to map compound-target-disease relationships. Molecular docking and molecular dynamics simulations assess stability and interactions, while animal experiments validate key targets and pathways in vivo. Findings show ZJP suppresses inflammatory and oncogenic signals and reverses PLGC progression through inhibition of the MEK/ERK/c-Myc pathway.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/zuojin-pill-alleviates-precancerous-lesions-of-gastric-cancer-mekerkc-myc-pathway-network-pharmacology-molecular-dynamics-and-experimental-validation/337145/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/zuojin-pill-alleviates-precancerous-lesions-of-gastric-cancer-mekerkc-myc-pathway-network-pharmacology-molecular-dynamics-and-experimental-validation/337145.png","ImageObject",300,407,{"name":92,"@type":93},"Genevieve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What problem does the study address about precancerous lesions of gastric cancer (PLGC)?","Question",{"text":112,"@type":113},"PLGC is a critical stage with a high risk of malignancy. Current approaches such as Helicobacter pylori eradication have limited ability to reverse key precancerous molecular changes.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the research determine ZJP’s active components and targets?",{"text":117,"@type":113},"It identifies active components using UPLC-QOrbitrap HRMS, then applies network pharmacology to build a “ZJP compound-target-disease” network. Molecular docking and molecular dynamics simulations evaluate interactions with core protein targets.",{"name":119,"@type":110,"acceptedAnswer":120},"Which biological pathway and molecular effects does ZJP show in the PLGC model?",{"text":121,"@type":113},"ZJP downregulates IL-6, TNF-α, c-myc, p-MEK1, and p-ERK1/2, and reverses PLGC progression. The mechanism is proposed to involve inhibition of the MEK/ERK/c-myc pathway and modulation of proliferation and apoptosis.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337145,1790126272,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374391974585,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Drug Design, Development and Therapy Dovepress  \n Open Access Full Text Article ORIGINAL RESEARCH  \nZuojin Pill Alleviates Precancerous Lesions of Gastric Cancer by Modulating the MEK/ERK/c-Myc Pathway: An Integrated Approach of Network Pharmacology, Molecular Dynamics Simulation, and Experimental Validation  \nLan Liang 1 , 2 , *, Chenming He 3 , *, Xue Han4 , *, Jia Liu 5 , Liuhong Yang 5 , Fengjiao Chang 6 , Yami Zhang 7 , Jie Lin 5 , 8  \n1The First Clinical Medical School, Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China; 2College of Nursing, Shaanxi Energy Institute, Xianyang, People’s Republic of China; 3LongHua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China; 4Xijing 986 Hospital Department, Air Force Medical University, Xian, People’s Republic of China; 5School of Basic Medical Sciences, Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China; 6School of Nursing, Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China; 7The Fifth Oncology Department, Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, People’s Republic of China; 8Shaanxi Provincial Key Laboratory of TCM Constitution and Disease Prevention, Xianyang, People’s Republic of China  \n*These authors contributed equally to this work  \nCorrespondence: Jie Lin; Yami Zhang, Email [linjie0921@sohu.com](linjie0921@sohu.com); [zhangyamiysh@163.com](zhangyamiysh@163.com)  \nBackground: Precancerous lesions of gastric cancer (PLGC) represent critical stages in gastric cancer progression, with a high risk of malignancy. Current treatments, such as Helicobacter pylori eradication, show limited efficacy in reversing precancerous molecular changes. Zuojin Pill (ZJP), a traditional Chinese medicine, has demonstrated potential for treating digestive disorders and may offer a promising approach for PLGC intervention.  \nObjective: This study aims to investigate the therapeutic effects and mechanisms of ZJP in treating PLGC, focusing on its active components, target pathways, and molecular interactions. By using advanced analytical techniques, we provide a scientific foundation for ZJP’s potential application in early gastric cancer intervention.  \nMethods: Using ultra-high performance liquid chromatography-quadrupole orbitrap high-resolution mass spectrometry (UPLC-QOrbitrap HRMS), we identified active components in ZJP. A network pharmacology approach was then applied to construct a “ZJPcompound-target-disease” network. Molecular docking and molecular dynamics simulations were conducted to analyze the stability and interactions of the main active components of ZJP with core protein targets in PLGC. Animal experiments were used to validate significant targets and pathways in vivo.  \nResults: Tangeritin, Isorhamnetin, Caffeic Acid, Azelaic Acid, and Adenosine were identified as the main active components of ZJPin the treatment of PLGC, with key targets including PIK3R1, MAPK3, SRC, JAK2, STAT3, and PIK3CA. Molecular docking and molecular dynamics simulations further confirmed the relationship between compounds and target proteins. The potential molecular mechanism of ZJP predicted by network pharmacology analysis was confirmed in PLGC rats. ZJP downregulated IL-6, TNF-α, c-myc, p-MEK1 and p-ERK1/2, effectively reversing the progression of PLGC.  \nConclusion: ZJP can reverse MNNG-induced PLGC, potentially through inhibition of the MEK/ERK/c-myc pathway and regulation of cellular proliferation and apoptosis.  \nKeywords: precancerous lesions gastric cancer, Zuojin Pill, network pharmacology, molecular dynamics simulations, ERK  \nReceived: 12 September 2024  \nAccepted: 21 November 2024  \nPublished: 11 December 2024  \nDrug Design, Development and Therapy 2024:18 5905–5929 5905  \n© 2024 Liang et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at [https://www.dovepress.com/terms","cbCaihBpCDObCtqK","https://ap.wps.com/l/cbCaihBpCDObCtqK","pdf",11267501,25,"English","# Introduction\n## Background and clinical significance of PLGC\n## Correa cascade and inflammation-cancer transformation\n# Methods\n## Component identification by UPLC-QOrbitrap HRMS\n## Network pharmacology and target mapping\n## Molecular docking and molecular dynamics simulation\n## Animal experiments for in vivo validation\n# Results\n## Main active components and key targets\n## Docking and simulation confirmation\n## Mechanistic validation in PLGC rats\n# Conclusion","[{\"question\":\"What problem does the study address about precancerous lesions of gastric cancer (PLGC)?\",\"answer\":\"PLGC is a critical stage with a high risk of malignancy. Current approaches such as Helicobacter pylori eradication have limited ability to reverse key precancerous molecular changes.\"},{\"question\":\"How does the research determine ZJP’s active components and targets?\",\"answer\":\"It identifies active components using UPLC-QOrbitrap HRMS, then applies network pharmacology to build a “ZJP compound-target-disease” network. Molecular docking and molecular dynamics simulations evaluate interactions with core protein targets.\"},{\"question\":\"Which biological pathway and molecular effects does ZJP show in the PLGC model?\",\"answer\":\"ZJP downregulates IL-6, TNF-α, c-myc, p-MEK1, and p-ERK1/2, and reverses PLGC progression. The mechanism is proposed to involve inhibition of the MEK/ERK/c-myc pathway and modulation of proliferation and apoptosis.\"}]","Zuojin Pill Alleviates Precancerous Lesions of Gastric Cancer - MEK/ERK/c-Myc Pathway Network Pharmacology Molecular Dynamics and Experimental Validation | PDF",1790017877,63,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6c8708516680ebbded01a075ab3637ab.webp",983,1272,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dcaa4b5622a62bff60aa7eb0d148905.webp",982,1270,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e288724e07c05cabfa2776a2a3add7fa.webp",981,1269,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4156e0f1b21d8bdb2f5fe4b1e1a49451.webp",980,1268]